Back to News
Oct 22, 2025 12:00 PM

Boston Scientific Jumps On Strong Guidance, Heart Devices Fuel Topline Growth

Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion on Wednesday, beating the consensus estimate of $4.97 billion.

The medical technology giant reported adjusted earnings of 75 cents, beating the consensus of 71 cents and the management guidance of 70-72 cents.

Sales increased 20.3% on a reported basis, compared to the company’s guidance range of 17%-19%, and 19.4% on an operational basis, 15.3% on an organic basis, compared to the company’s guidance range of 12%-14%.

The company’s cardiovascular segment generated sales of $3.34 ...